The most striking development in colorectal cancer over the past three years isn't a single drug — it's the realization of how molecularly heterogeneous the disease is, and how dramatically that heterogeneity determines treatment response. MSI-H tumors — about 5% of metastatic cases — respond to pembrolizumab so well that immunotherapy has moved from third-line rescue to first-line standard of care. MSS tumors, which make up the vast majority of metastatic CRC, remain largely resistant to checkpoint inhibition despite enormous trial investment, and figuring out why — and what to do about it — is the central unsolved problem in the field. The 2026 pipeline reflects both the consolidation of proven strategies and a genuine search for answers in MSS disease.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Colorectal cancer (CRC) is the second leading cause of cancer death in the US, with approximately 153,000 new cases diagnosed annually. Comprehensive molecular profiling has made it clear that metastatic CRC is not one disease — MSI-H/dMMR, KRAS G12C, BRAF V600E, HER2-amplified, and NTRK-fusion subtypes each have distinct biology, prognosis, and now approved targeted treatments. In 2026, the active trial landscape spans ctDNA-guided adjuvant therapy decisions, KRAS G12C combination strategies, HER2-directed antibody-drug conjugates, and the still-unsolved challenge of MSS immunotherapy resistance.
Immunotherapy in MSI-H/dMMR CRC: What's Been Proven and What's Next
The KEYNOTE-177 trial established pembrolizumab as first-line standard of care for MSI-H/dMMR metastatic CRC in 2021, reporting a progression-free survival of 16.5 months vs. 8.2 months with FOLFOX/FOLFIRI ± bevacizumab, with an objective response rate of 43.8% vs. 33.1%. Five-year follow-up data published in 2024 confirmed durable responses: 28% of pembrolizumab-treated patients were progression-free at 5 years — a number that would have been unimaginable in metastatic CRC a decade ago. Nivolumab ± ipilimumab (CheckMate 142) is also approved for previously treated MSI-H mCRC, with the combination showing 55% ORR in a pre-treated population.
The most clinically striking development in this space has been the neoadjuvant immunotherapy story in MSI-H locally advanced rectal cancer. Andrea Cercek and colleagues at Memorial Sloan Kettering published data showing pembrolizumab given as neoadjuvant monotherapy before surgery produced complete clinical responses (cCR) in up to 100% of MSI-H rectal cancer patients in their prospective series. Complete responders underwent "watch and wait" — surveillance without surgery — avoiding permanent colostomy and the morbidity of pelvic resection. This is a paradigm shift: it's no longer a marginal treatment modification, it's a fundamentally different treatment strategy for a subgroup of patients. Phase 3 trials formalizing organ-preservation approaches in MSI-H rectal cancer (NCT04165772 and the UK PEMREC trial) are now enrolling.
The unsolved problem is MSS disease. Multiple trials combining checkpoint inhibitors with MEK inhibitors, anti-VEGF agents, and IDO1 inhibitors have failed to crack MSS resistance. The CODEL trial in glioblastoma's failure to sensitize MSS tumors through IDO pathway inhibition has parallels in CRC. Active 2026 trials are exploring bispecific antibodies, TIL (tumor-infiltrating lymphocyte) therapy, and microbiome modulation as strategies to create MSS tumors that are no longer immune-excluded.
KRAS G12C Inhibitors: From Single-Agent Disappointment to Combination Efficacy
KRAS mutations are present in approximately 45% of colorectal cancers. For decades, KRAS was called "undruggable" — its GTP-binding surface offers no obvious allosteric pocket. The breakthrough came from a structural insight: KRAS G12C mutations create a novel cysteine residue adjacent to the switch-II pocket that allows covalent inhibition specifically when KRAS is in its GDP-bound inactive state. Sotorasib (Lumakras, AMG 510) and adagrasib (Krazati, MRTX849) were developed as covalent KRAS G12C inhibitors and approved for NSCLC, where single-agent ORRs of 37–43% validated the approach.
In CRC, single-agent KRAS G12C inhibition was a disappointment. Sotorasib monotherapy showed only 9.7% ORR in the CodeBreak 100 CRC cohort; adagrasib monotherapy achieved 19.5% ORR in KRYSTAL-1. The CRC data stands in sharp contrast to NSCLC. The mechanistic explanation is EGFR feedback activation: in CRC cells, KRAS G12C inhibition triggers rapid compensatory reactivation of upstream EGFR signaling, which reactivates the very pathway being blocked. The solution — combine KRAS G12C inhibition with EGFR blockade — was confirmed in the CODEBREAK 300 trial (sotorasib + panitumumab), which reported a 49% ORR vs. 2% for sotorasib monotherapy. This combination received FDA approval in 2024 and is now standard of care for KRAS G12C-mutated CRC after prior chemotherapy.
Adagrasib + cetuximab is the competing combination, showing 46% ORR in the KRYSTAL-10 cohort — similar efficacy profile. The 2026 clinical question is whether these combinations can move earlier in the treatment sequence; multiple Phase 2/3 trials are evaluating first-line KRAS G12C + EGFR inhibition vs. standard FOLFOX chemotherapy backbone.
HER2-Targeted Therapy: From Marginalized Subgroup to Actionable Target
HER2 amplification or overexpression is present in approximately 3–5% of metastatic CRC — a small number in absolute terms, but significant given CRC's prevalence. Unlike breast cancer where HER2 overexpression correlates with high proliferation and chemotherapy sensitivity, HER2-positive CRC behaves differently and was historically undertreated.
The MOUNTAINEER trial was the pivotal study: tucatinib (a highly selective HER2 tyrosine kinase inhibitor) combined with trastuzumab showed 38.1% ORR and median overall survival of 24.1 months in heavily pre-treated HER2-positive CRC patients. This led to FDA approval in August 2023. The DESTINY-CRC02 trial established trastuzumab deruxtecan (T-DXd) as a second option, showing 45.3% ORR at the 5.4 mg/kg dose with median PFS of 6.9 months.
The key clinical principle is that HER2 testing must now be reflexly performed in all metastatic CRC patients — not only when other targets are negative. Current NCCN guidelines recommend HER2 IHC/FISH testing at diagnosis. Active 2026 trials are moving T-DXd into earlier lines and evaluating combinations with chemotherapy backbone. The DESTINY-CRC03 trial is testing T-DXd vs. chemotherapy in second-line HER2-positive CRC, with results anticipated in 2026.
ctDNA-Guided Adjuvant Therapy: The Liquid Biopsy Revolution in Stage II–III CRC
The ctDNA story in CRC is one of the most clinically relevant developments in oncology of the past five years, and it's still unfolding. The premise: circulating tumor DNA detected in blood after surgical resection identifies molecular residual disease (MRD) — microscopic deposits of tumor that are invisible on imaging but will eventually grow into clinical recurrence. ctDNA-positive patients post-resection have recurrence rates of 60–80%; ctDNA-negative patients have recurrence rates of 5–10%. This stratification is far more precise than current clinicopathological staging.
The DYNAMIC trial in Australia (NEJM 2022) was the proof-of-concept study: ctDNA-guided chemotherapy decisions in Stage II colon cancer were non-inferior to standard staging-based decisions — and reduced the proportion of patients receiving adjuvant chemotherapy by 50%, sparing toxicity in low-risk patients without compromising survival outcomes. The absolute benefit: ctDNA-guided decision-making eliminated unnecessary chemotherapy in approximately 1 in 3 Stage II patients without the expected increase in recurrence.
Confirmatory trials are now the active question. COBRA (NCT04068103, NCI-sponsored) and CIRCULATE-US are evaluating ctDNA-guided escalation and de-escalation in Stage II and III colon cancer. The ALTAIR trial in Japan showed that ctDNA-positive patients who received immunotherapy in the MSI-H subgroup showed improved outcomes, suggesting ctDNA could guide treatment selection as well as treatment decision. The FDA has not yet approved ctDNA for routine adjuvant guidance, but multiple regulatory submissions are anticipated in 2026 based on COBRA primary analysis data expected mid-year.
Practical implication: if you have Stage II or III colon cancer and have not been offered ctDNA testing after surgery, ask your oncologist whether it's available through a clinical trial — COBRA remains actively enrolling at sites across the US.
Key Takeaways
- Pembrolizumab is first-line standard of care for MSI-H/dMMR metastatic CRC (KEYNOTE-177: PFS 16.5 vs. 8.2 months), and complete neoadjuvant responses in MSI-H rectal cancer are enabling organ-preservation "watch and wait" approaches in Phase 3 trials.
- KRAS G12C single-agent inhibitors show only 9–19% ORR in CRC due to EGFR feedback reactivation; the FDA-approved combination of sotorasib + panitumumab achieves 49% ORR by blocking this resistance mechanism.
- HER2-amplified CRC (~3–5% of cases) is now targetable with tucatinib + trastuzumab (FDA-approved August 2023, 38% ORR) and trastuzumab deruxtecan (45% ORR in DESTINY-CRC02). HER2 testing should be reflexly performed at diagnosis.
- The DYNAMIC trial showed ctDNA-guided adjuvant decisions were non-inferior to standard staging while eliminating chemotherapy in 50% of Stage II patients — confirmatory trials COBRA and CIRCULATE-US are enrolling with FDA submissions expected in 2026.
- Comprehensive molecular profiling (MSI, KRAS, BRAF V600E, HER2, NTRK, RAS) is now essential for all metastatic CRC patients before treatment decisions — each molecular subtype has at least one approved targeted option or active late-stage trial.